Dexrazoxane to Prevent Cardiotoxicity in Adults Treated with Anthracyclines-Reference-Cited by-同舟云学术

Dexrazoxane to Prevent Cardiotoxicity in Adults Treated with Anthracyclines

Published:2024-04 Issue:2 Volume:6 Page:322-324
ISSN:2666-0873
Container-title:JACC: CardioOncology
language:en
Short-container-title:JACC: CardioOncology

Author:

Upshaw Jenica N.,Parson Susan K.,Buchsbaum Rachel J.,Schlam Ilana,Ruddy Kathryn J.,Durani Urshila,Epperla Narendranath,Leong Darryl P.^ORCID

Publisher

Elsevier BV

Reference9 articles.

1. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines;de Baat;Cochrane Database Syst Rev,2022

2. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy;Marty;Ann Oncol,2006

3. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer;O’Brien;Ann Oncol,2004

4. Prospective evaluation of doxorubicin cardiotoxicity in patients with advanced soft-tissue sarcoma treated in the ANNOUNCE phase III randomized trial;Jones;Clin Cancer Res,2021

5. Preexisting cardiovascular risk and subsequent heart failure among non-Hodgkin lymphoma survivors;Salz;J Clin Oncol,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research Progress on the Mechanism, Monitoring, and Prevention of Cardiac Injury Caused by Antineoplastic Drugs—Anthracyclines;Biology;2024-09-03